Evaluation of 18-F-fluoro-2-deoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) as a staging and monitoring tool for dogs with stage-2 splenic hemangiosarcoma - A pilot study

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Positron Emission Tomography-Computed Tomography (PET-CT) is routinely used for staging and monitoring of human cancer patients and is becoming increasingly available in veterinary medicine. In this study, 18-fluorodeoxyglucose (18 FDG)-PET-CT was used in dogs with naturally occurring splenic hemangiosarcoma (HSA) to assess its utility as a staging and monitoring modality as compared to standard radiography and ultrasonography. Nine dogs with stage-2 HSA underwent18 FDG-PET-CT following splenectomy and prior to commencement of chemotherapy. Routine staging (thoracic radiography and abdominal ultrasonography) was performed prior to18 FDG-PET-CT in all dogs. When abnormalities not identified on routine tests were noted on18 FDG-PET-CT, owners were given the option to repeat a PET-CT following treatment with eBAT. A PET-CT scan was repeated on Day 21 in three dogs. Abnormalities not observed on conventional staging tools, and most consistent with malignant disease based on location, appearance, and outcome, were detected in two dogs and included a right atrial mass and a hepatic nodule, respectively. These lesions were larger and had higher metabolic activity on the second scans.18 FDG-PET-CT has potential to provide important prognostic information and influence treatment recommendations for dogs with stage-2 HSA. Additional studies will be needed to precisely define the value of this imaging tool for staging and therapy monitoring in dogs with this and other cancers.

Original languageEnglish (US)
Article numbere0172651
JournalPloS one
Volume12
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

2-deoxyglucose
positron-emission tomography
hemangiosarcoma
Hemangiosarcoma
Positron emission tomography
Deoxyglucose
computed tomography
Tomography
Dogs
Monitoring
monitoring
dogs
Ultrasonography
Radiography
radiography
ultrasonography
Veterinary medicine
Thoracic Radiography
neoplasms
Veterinary Medicine

Cite this

@article{fdd6ad7d71ac4d9cb3bf5db9435067c5,
title = "Evaluation of 18-F-fluoro-2-deoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) as a staging and monitoring tool for dogs with stage-2 splenic hemangiosarcoma - A pilot study",
abstract = "Positron Emission Tomography-Computed Tomography (PET-CT) is routinely used for staging and monitoring of human cancer patients and is becoming increasingly available in veterinary medicine. In this study, 18-fluorodeoxyglucose (18 FDG)-PET-CT was used in dogs with naturally occurring splenic hemangiosarcoma (HSA) to assess its utility as a staging and monitoring modality as compared to standard radiography and ultrasonography. Nine dogs with stage-2 HSA underwent18 FDG-PET-CT following splenectomy and prior to commencement of chemotherapy. Routine staging (thoracic radiography and abdominal ultrasonography) was performed prior to18 FDG-PET-CT in all dogs. When abnormalities not identified on routine tests were noted on18 FDG-PET-CT, owners were given the option to repeat a PET-CT following treatment with eBAT. A PET-CT scan was repeated on Day 21 in three dogs. Abnormalities not observed on conventional staging tools, and most consistent with malignant disease based on location, appearance, and outcome, were detected in two dogs and included a right atrial mass and a hepatic nodule, respectively. These lesions were larger and had higher metabolic activity on the second scans.18 FDG-PET-CT has potential to provide important prognostic information and influence treatment recommendations for dogs with stage-2 HSA. Additional studies will be needed to precisely define the value of this imaging tool for staging and therapy monitoring in dogs with this and other cancers.",
author = "Antonella Borgatti and Winter, {Amber L.} and Kathleen Stuebner and Ruth Scott and Ober, {Christopher P.} and Anderson, {Kari L.} and Feeney, {Daniel A.} and Vallera, {Daniel A.} and Koopmeiners, {Joseph S.} and Modiano, {Jaime F.} and Jerry Froelich",
year = "2017",
month = "2",
day = "1",
doi = "10.1371/journal.pone.0172651",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Evaluation of 18-F-fluoro-2-deoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) as a staging and monitoring tool for dogs with stage-2 splenic hemangiosarcoma - A pilot study

AU - Borgatti, Antonella

AU - Winter, Amber L.

AU - Stuebner, Kathleen

AU - Scott, Ruth

AU - Ober, Christopher P.

AU - Anderson, Kari L.

AU - Feeney, Daniel A.

AU - Vallera, Daniel A.

AU - Koopmeiners, Joseph S.

AU - Modiano, Jaime F.

AU - Froelich, Jerry

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Positron Emission Tomography-Computed Tomography (PET-CT) is routinely used for staging and monitoring of human cancer patients and is becoming increasingly available in veterinary medicine. In this study, 18-fluorodeoxyglucose (18 FDG)-PET-CT was used in dogs with naturally occurring splenic hemangiosarcoma (HSA) to assess its utility as a staging and monitoring modality as compared to standard radiography and ultrasonography. Nine dogs with stage-2 HSA underwent18 FDG-PET-CT following splenectomy and prior to commencement of chemotherapy. Routine staging (thoracic radiography and abdominal ultrasonography) was performed prior to18 FDG-PET-CT in all dogs. When abnormalities not identified on routine tests were noted on18 FDG-PET-CT, owners were given the option to repeat a PET-CT following treatment with eBAT. A PET-CT scan was repeated on Day 21 in three dogs. Abnormalities not observed on conventional staging tools, and most consistent with malignant disease based on location, appearance, and outcome, were detected in two dogs and included a right atrial mass and a hepatic nodule, respectively. These lesions were larger and had higher metabolic activity on the second scans.18 FDG-PET-CT has potential to provide important prognostic information and influence treatment recommendations for dogs with stage-2 HSA. Additional studies will be needed to precisely define the value of this imaging tool for staging and therapy monitoring in dogs with this and other cancers.

AB - Positron Emission Tomography-Computed Tomography (PET-CT) is routinely used for staging and monitoring of human cancer patients and is becoming increasingly available in veterinary medicine. In this study, 18-fluorodeoxyglucose (18 FDG)-PET-CT was used in dogs with naturally occurring splenic hemangiosarcoma (HSA) to assess its utility as a staging and monitoring modality as compared to standard radiography and ultrasonography. Nine dogs with stage-2 HSA underwent18 FDG-PET-CT following splenectomy and prior to commencement of chemotherapy. Routine staging (thoracic radiography and abdominal ultrasonography) was performed prior to18 FDG-PET-CT in all dogs. When abnormalities not identified on routine tests were noted on18 FDG-PET-CT, owners were given the option to repeat a PET-CT following treatment with eBAT. A PET-CT scan was repeated on Day 21 in three dogs. Abnormalities not observed on conventional staging tools, and most consistent with malignant disease based on location, appearance, and outcome, were detected in two dogs and included a right atrial mass and a hepatic nodule, respectively. These lesions were larger and had higher metabolic activity on the second scans.18 FDG-PET-CT has potential to provide important prognostic information and influence treatment recommendations for dogs with stage-2 HSA. Additional studies will be needed to precisely define the value of this imaging tool for staging and therapy monitoring in dogs with this and other cancers.

UR - http://www.scopus.com/inward/record.url?scp=85013652702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013652702&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0172651

DO - 10.1371/journal.pone.0172651

M3 - Article

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0172651

ER -